» Articles » PMID: 1431015

Paroxetine: an Overview of Dosage, Tolerability, and Safety

Overview
Specialty Pharmacology
Date 1992 Jun 1
PMID 1431015
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Paroxetine is a new selective serotonin reuptake inhibitor which has been extensively evaluated as an antidepressant in clinical trials and a large computerized safety database has been accumulated. A comprehensive review of data on dosage supports the recommendation that 20 mg paroxetine daily is the optimal therapeutic dose for most patients. When compared to active controls--mainly tricyclic antidepressants--paroxetine was found to have a different adverse-event profile with fewer anticholinergic, cardiovascular and nervous system events but more gastrointestinal events, particularly nausea. However, these events were not severe and did not usually lead to discontinuation of treatment. The adverse events reported with paroxetine were most likely to occur early in the course of treatment and there was no evidence of any increase in events in the elderly or with longer-term treatment. Paroxetine was not associated with excess of death from any cause, suicides, suicide attempts or serious life-threatening events. No clinically significant drug-related abnormalities were reported in laboratory monitoring, including liver function tests, in short- or long-term use. Finally, and importantly for an antidepressant, paroxetine appears relatively safe in overdose.

Citing Articles

Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.

Johnson C, Maxwell M, Williams B, Dougall N, MacGillivray S BMJ Med. 2023; 1(1):e000017.

PMID: 36936596 PMC: 9978765. DOI: 10.1136/bmjmed-2021-000017.


Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression.

Kamijima K, Hashimoto S, Nagayoshi E, Koyama T Neuropsychiatr Dis Treat. 2013; 9:555-65.

PMID: 23650446 PMC: 3640608. DOI: 10.2147/NDT.S42915.


Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Foster R, Goa K CNS Drugs. 2013; 8(2):163-88.

PMID: 23338224 DOI: 10.2165/00023210-199708020-00010.


Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Adli M, Baethge C, Heinz A, Langlitz N, Bauer M Eur Arch Psychiatry Clin Neurosci. 2005; 255(6):387-400.

PMID: 15868067 DOI: 10.1007/s00406-005-0579-5.


Cell transplantation for Parkinson's disease: present status.

Drucker-Colin R, Verdugo-Diaz L Cell Mol Neurobiol. 2004; 24(3):301-16.

PMID: 15206816 PMC: 11529974. DOI: 10.1023/b:cemn.0000022764.94760.3f.